F3 Expression Drives Sensitivity to the Antibody-Drug Conjugate Tisotumab Vedotin in Glioblastoma.

BACKGROUND/OBJECTIVES: The gene F3, encoding Tissue Factor (TF), is expressed in many cancers and contributes to their malignancy. Among adult-type diffuse gliomas, IDH1/2 wild-type (IDH(wt)) glioblastomas (GBM) express more TF than IDH1/2 mutant (IDH(mut)) gliomas. Tisotumab vedotin (TisVed), an anti-TF antibody conjugated to monomethyl auristatin E, is a therapeutic designed to target cells expressing TF. We therefore sought to determine the therapeutic potential of TisVed in IDH(wt) vs. IDH(mut) gliomas. METHODS: We treated IDH(wt) and IDH(mut) patient-derived glioma cells with control IgG, unconjugated tisotumab (Tis), or TisVed in vitro, followed by cell viability assays and the assessment of TF signaling. We tested Tis and TisVed in mice intracranially engrafted with patient-derived IDH(wt) and IDH(mut) gliomas and mice flank engrafted with IDH(wt) GBM. RESULTS: TisVed was more active against cultured IDH(wt) GBM cells than IDH(mut) glioma cells. This activity was increased by the daily washout of soluble TF secreted by IDH(wt) GBM cells. Unconjugated Tis had less effect than TisVed, and TF signaling was minimally inhibited. TisVed extended the survival of mice intracranially engrafted with IDH(wt) GBM (p = 0.006), but not mice with IDH(mut) glioma (p = 0.88). TisVed also reduced the growth of IDH(wt) GBM flank xenografts. Tis alone had no antitumor effect in either setting. Notably, both TisVed and Tis were associated with hemorrhage in flank tumors. CONCLUSIONS: TisVed targets high-TF-expressing IDH(wt) GBM, but not low-TF-expressing IDH(mut) glioma. This is predominately through the vedotin conjugate rather than inhibition of TF signaling. Though the effect size is modest, TisVed shows anticancer effects against IDH(wt) GBM. However, there could be complications related to hemostasis and hemorrhage.